When nucleoside chemistry met hypervalent iodine reagents

Mahesh K. Lakshman and Barbara Zajc

Department of Chemistry & Biochemistry, The City College of New York, 160 Convent Avenue, New York, NY 10031, USA, and The Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, NY 10016, USA

Email: mlakshman@ccny.cuny.edu, bzajc@ccny.cuny.edu

Dedicated to Professor Kenneth Laali on the occasion of his 65\textsuperscript{th} birthday

Received 07-28-2017  
Accepted 10-22-2017  
Published on line 12-21-2017

Abstract

There has been increasing use of hypervalent iodine reagents in the field of nucleoside chemistry. Applications span: (a) synthesis of nucleoside analogues with sulfur and seleno sugar surrogates, (b) synthesis of unusual carbocyclic and ether ring-containing nucleosides, (c) introduction of sulfur and selenium into pyrimidine bases of nucleosides and analogues, (d) synthesis of isoxazole and isoxazoline ring-containing nucleoside analogues, (e) involvement of purine ring nitrogen atoms for remote C–H bond oxidation, and (f) metal-catalyzed and uncatalyzed synthesis of benzimidazolyl purine nucleoside analogues by intramolecular C–N bond formation. This review offers a perspective on developments involving the use of hypervalent iodine reagents in the field of nucleoside chemistry that have appeared in the literature in the 2003–2017 time frame.

Keywords: Hypervalent iodine, nucleosides, C–N bond formation, C–H bond activation, nucleoside analogs
Table of Contents

1. Introduction
2. Glycosylation-Type Reactions Leading to Nucleoside Analogues
3. Miscellaneous Hypervalent Iodine Reagent Mediated Nucleoside Modifications
4. Purinyl N-Directed C–H Bond Oxidation by PIDA
5. Cu-Catalyzed Intramolecular C–N Bond Formation in Purine Nucleosides Using PIDA
7. Pd-Catalyzed and Metal-Free Intramolecular C–N Bond Formation Leading to Isomeric Carbazolyl and Benzimidazolyl Purine Nucleoside Analogues Using PIDA
8. Conclusions
   References

1. Introduction

Nucleosides are important biomolecules, present in all living systems and, thus, constitute a highly important class of compounds. They are fundamental building blocks of genetic material and because of this they are important scaffolds for development of new compounds with diverse applications. Predominantly, nucleosides and their analogues have been at the forefront in pharmaceuticals and medicine, as antiviral, anticancer, and antibiotic agents. \(^{1-10}\) In addition, they serve as biological probes and imaging agents. \(^{11-19}\)

The eight natural nucleosides are shown in Figure 1. Two possess a purine heterocyclic aglycone and three a pyrimidine, and they all share commonalities in the saccharide moiety. The deoxyribosides possess an H atom at position 2’ (X in Figure 1) whereas the ribosides have an OH at this position. In the quest for novel nucleoside analogues for the aforementioned applications, both the aglycone and the saccharide have been the subject of diverse modifications.

**Figure 1.** The eight naturally occurring nucleosides.

Hypervalent iodine reagents are generally readily available and easy-to-handle. For this reason they are seeing wide applications in organic synthesis and methodology development. The most commonly encountered reagents have either $\lambda^3$- or $\lambda^5$-iodine, and structures of the routinely encountered ones are shown in Figure 2 (PIDA = (diacetoxyiodo)benzene, PIFA = [bis(trifluoroacetoxy)iodo]benzene, IOB =
iodosylbenzene or iodosobenzene, HTIB = [(hydroxy)(tosyloxy)iodo]benzene or Koser’s reagent, IBX = 2-iodoxybenzoic acid, and DMP = Dess-Martin periodinane).

![Figure 2](image)

**Figure 2.** Commonly encountered $\lambda^3$ and $\lambda^5$ hypervalent iodine reagents.

In this review, we describe some of the applications of hypervalent iodine reagents to the field of nucleoside modification.

## 2. Glycosylation-Type Reactions Leading to Nucleoside Analogues

In 2003, the use of hypervalent iodine reagents was demonstrated for the synthesis of pyrimidine nucleoside analogues containing a sulfur atom in the sugar-like portion. Initial experiments involved reactions of tetrahydrothiophene and thymine. With 2 equiv. of thymine and 6 equiv. each of TMSOTf and Et₃N, and 1.2 equiv. of PIFA, in CH₂Cl₂ at 0 °C, an excellent 80% yield of 1-(tetrahydrothiophen-2-yl)thymine was obtained.

The next step was the assessment of the reaction with tetrahydrothiophene derivatives decorated with additional hydroxyl groups. As shown in Scheme 1, cis-2-butene-1,4-diol 1 was converted to the protected dihydroxytetrahydrothiophene 2 via 8 steps (PMBz = p-methoxybenzoyl). Two hypervalent iodine reagents, PIFA and IOB, were tested for the “glycosylation”. An anomic mixture of compound 3 was obtained. Variation of conditions using PIFA altered the anomer ratio and the best 5 : 1 $\beta/\alpha$ ratio was obtained with 3 equiv. each of thymine, TMSOTf, and 2 x 4 equiv. of Et₃N (yield of 3 was 65%). With IOB, only the $\beta$ anomer was formed (61%).

Next a synthesis of a ribosyl analogue of uracil was sought. Starting from d-ribose, the tetrahydrothiophene 4 was synthesized. Evaluation of PIFA and IOB indicated the latter to be superior at 0 °C. Whereas PIFA gave a 5 : 1 ratio of anomers, IOB gave exclusively the $\beta$-anomer 5 in 53% yield. The latter outcome is consistent with the formation of a thionium cation that is also stabilized by the neighboring PMBz ester. Final deprotection of the silyl and ester groups yielded the desired compound 6 (66%).
Scheme 1. Synthesis of a higher order thymine nucleoside analogue and a plausible mechanism.

In 2008, the synthesis of purine nucleoside analogues containing a thiosaccharide analogue was reported. As in Scheme 1, the dibenzoate analogue of tetrahydrothiophene diol 7 was utilized in initial reactions with three purine derivatives as shown in Scheme 3.

Scheme 2. Synthesis of a thio analogue of uridine.

In 2008, the synthesis of purine nucleoside analogues containing a thiosaccharide analogue was reported. As in Scheme 1, the dibenzoate analogue of tetrahydrothiophene diol 7 was utilized in initial reactions with three purine derivatives as shown in Scheme 3.

Scheme 3. Reactions of three purines with a tetrahydrothiophenediol dibenzoate.

Reaction of 6-chloropurine did not proceed with IOB, but product 8 (35%) was obtained with 1.5 equiv. of PIFA, 10 equiv. each of TMSOTf and Et$_3$N. Under these conditions, 2-fluoro-6-chloropurine and 2,6-dichloropurine also reacted giving the respective products, 9 and 10, in 36 and 72% yields, respectively. In each case α/β anomers were observed; 1 : 5 with 6-chloropurine, 1 : 3 with 2-fluoro-6-chloropurine, and 1 : 15
with 2,6-dichloropurine. The isolated β-isomers were ammonolyzed to yield the C6-amino products (11: quantitative, 12: 81%, and 13: 67%).

Next four precursors, 15-18, were prepared from D-glucono-γ-lactone via 1,4-anhydro-2,3-isopropylidene-4-thio-D-ribitol 14. These compounds differed in protecting groups that were used. When compound 15 was reacted with 6-chloropurine, PIFA, TMSOTf, and Et₃N, quite surprisingly, compound 19 (54%) was isolated with no trace of the desired 21.

![Scheme 4. Reactions of 6-chloropurine with differentially protected tetrahydothiophene derivatives.](image)

On the other hand, the use of precursor 16 did lead to the desired 22 (16% + 12% of the N⁷ isomer) and about 5% of 20. But use of 17 and 18 both led to the desired products 23 (11% + 17% of the N⁷ isomer) and 24 (22% + 17% of the N⁷ isomer), respectively. These data show that the reaction can partition between two cationic species (Figure 3). The authors proposed that in substrate 15, the PMBz group is less electron withdrawing than the Bz group in 16. Thus, the more acidic proton is removed, which in the case of 16 is at the less-substituted carbon atom, and this followed by capture by the purine at the desired center (see Scheme 1 for a mechanism). With substrates 17 and 18, they propose a significantly increased steric bulk at the silyl-protecting group, which then diverts deprotonation to the desired less-substituted carbon atom.

![Figure 3. Possible thionium cations that are proposed in the reactions.](image)

In order to test the hypothesis two compounds, 25 and 26, were synthesized from 14. These were subjected to reactions with 6-chloropurine (Scheme 5). From 25, 44% of 27 and 14% of 29 were obtained (in addition, 8% of the N⁷ isomer was formed).
Scheme 5. Testing the hypothesis on the role of protecting groups on sites of reactions.

By contrast, in the reaction of 26 with 6-chloropurine, <1% of 28 and 28% of 30 were obtained (along with 10% of the N7 isomer). This clearly showed that with 25 deprotonation occurred at the more-substituted carbon atom (more acidic proton was removed), whereas with 26, steric bulk directs deprotonation to the less-substituted carbon atom. Thioadenosine analogue 31 was then obtained by removal of the acetonide and silyl protection (66%) and ammonolysis (90%).

Another hypervalent iodine reagent, HTIB, has seen use in the synthesis of other thymidine nucleoside analogues.22 This chemistry in fact began with cis-2-butene-1,4-diol 1 (the precursor in Scheme 1) that was converted over 10 steps to the dibenzoyl thietane 32 (Scheme 6). Exposure of 32 to thymine, TMSOTf, Et3N, and HTIB in CH2Cl2 at 0 °C resulted in the five-membered nucleoside analogue 33 in 30% yield. Deprotection of 33 then gave product 34 (62%).

Scheme 6. Formation of a tetrahydrothiophene nucleoside analogue from a thietane.

Formation of product 33 rather than a thietane-derived product has been rationalized on the basis of neighboring group participation in the cis-isomer of precursor 32. This was supported by the isomerization shown in Scheme 7. On the basis of these observations, a proposed mechanism for the formation of 33 is shown in Scheme 7.

Just as with the synthesis of compound 4 (Scheme 2), a seleno analogue 35 was synthesized from D-ribose (Scheme 8, DMBz = 2,4-dimethoxybenzoyl).23 This synthesis was beset with isomerization problems, analogous to those in Scheme 7 but resulting in a 6-membered product from a 5-membered precursor. Nevertheless, compound 35 was attainable. IOB, PIFA, PIDA, and HTIB were investigated for the “glycosylation” step, in conjunction with Et3N or 2,6-lutidine as base. Best results were attained with 2 equiv. of uracil, 8 equiv. of TMSOTf, and 8 equiv. of 2,6-lutidine, in 1,2-dichloroethane at 50 °C. Under these conditions a 64% yield of product 36 was obtained and 13% of 35 was recovered.
Scheme 7. Isomerization of cis-32 and a mechanism for the formation of product 33.

Scheme 8. Synthesis of seleno analogues of uridine and cytidine.

Deprotection of 36 gave the seleno analogue of uridine (37, 66%, Scheme 8). The amide group in 36 was converted to the sym-isopropylbenzene sulfonate, which was subjected to displacement with ammonia to yield compound 38 (91%). Deprotection of this compound then gave the cytosine analogue 39 (64%, Scheme 8).

Most recently, synthesis of the seleno analogues of purine nucleosides have been reported. Initially, the authors attempted syntheses with the selenosaccharide analogue 35. However, this derivative was not useable; with 6-chloropurine the N\textsuperscript{7} “glycosylation” product was obtained with a hypervalent iodine reagent, but this could not be isomerized to the N\textsuperscript{9} isomer. On the other hand, reaction with 2-amino-6-chloropurine was unsuccessful. Thus, the authors pursued the use of 40, a variant of 26, that had previously been used in a Vorbrüggen coupling with the above-mentioned purines. In this work, the authors were able to isomerize the N\textsuperscript{7} “glycosylation” product to the N\textsuperscript{9} isomer, using TMSOTf (Scheme 9).
As shown in Scheme 9, acetonide-protected 40 was reacted with 2 equiv. of silylated 6-chloropurine in the presence of IOB, TMSOTf, and 2,6-lutidine. A shorter reaction time led to lower amounts of the undesired α-anomers but a lower reaction temperature led to a longer time for consumption of 40. However, the separated N\textsuperscript{7} isomer 42 was isomerized to 41 (overall 55% yield from 40).

Scheme 9. Synthesis of the seleno analogue of 6-chloropurine riboside.

Scheme 10. Reactions of seleno sugar analogue 40 with 2-amino-6-chloro and 2,6-dichloropurines, and further transformations to a protected seleno guanosine analogue.
Comparable chemistry was evaluated using 2-amino-6-chloropurine (Scheme 10). The desired N⁹ isomer (43) was a minor component (16%) with the N⁷ isomer (44) predominating in the product mixture (31%). However, in this case, the N⁷ isomer could not be isomerized to the N⁹ derivative. In studies with other purine derivatives, the authors discovered that an amino group is a detriment to both yield and the isomerization.

In contrast to the outcome with 2-amino-6-chloropurine and other purines, reaction of 2,6-dichloropurine with 40 proceeded well to give an isomeric mixture that was readily isomerized to give 45 in 62% yield (Scheme 10). This compound was subjected to selective ammonolysis at the C6 position (46: 95%) and diazotization/hydrolysis (47: 85%). The protected seleno guanosine analogue 48 was finally obtained by ammonolysis at the C2 position, under more forcing conditions (77%).

An interesting approach was undertaken for access to C-nucleoside analogues. Cyclopentadiene and cyclohexadiene were subjected to hydrosilylation followed by conversion to the triethoxy and trimethyl silanes (Scheme 11). These compounds were investigated for their reactions with bis(trimethylsilyl)uracil, promoted by TMSOTf and a hypervalent iodine reagent (IOB, PIDA, PIFA, and HTIB, see Scheme 11). Of these, PIDA gave the best outcome.

Scheme 11. Reactions of silyl derivatives of cyclopentene and cyclohexene with uracil.

Use of a chiral cyclohexene derivative returned a racemic product (Scheme 11). This indicated the formation of an allyl cation as a reactive intermediate that is captured by uracil. The next focus was the development of a synthesis of more substituted cyclohexene-based pyrimidine nucleoside analogues. For this, reaction of (E)-buta-1,3-dien-1-yltrimethylsilane was subjected to a [4 + 2] cycloaddition with dimethyl fumarate (Scheme 12). The 1:1 mixture of inseparable cycloadducts was reduced and silylated, resulting in separable 49a and 49b.

Each cyclohexene isomer (49a and 49b) was reacted with bis(trimethylsilyl)uracil, using PIDA, and TMSOTf. Isomer 49a reacted faster than 49b and in the case of the latter, unreacted starting material (20%) was reisolated. However, each precursor gave the four products 50a-d in different ratios. In order to separate the four products, the N3 position was benzoylated (51a-d in Scheme 13) and the product mixture was chromatographed. From this, compounds 51a and 51d were separated, whereas a mixture of 51b and 51c was obtained.

Debenzoylation of 51a-d gave 50a-d (two of which were separated). Sulfonation of the amides in 50a-d gave 52a-d, displacement with ammonia gave the silyl-protected compounds 53a-d. At this stage, all four isomers were separable. Final desilylation with n-Bu₄NF in THF gave the four cytidine analogues 54a-d.

Scheme 13. Synthesis of four isomeric cytidine nucleoside analogues.

In 2012, a method to access oxygen-containing uracil nucleoside analogues was reported. In this work, initially reactions of dihydropyran and dihydrofuran with bis(trimethylsilyl)uracil were assessed. Reaction of dihydropyran using 2 equiv. of bis(trimethylsilyl)uracil, 1.5 equiv. of PIDA, and 0.4 equiv. of TMSOTf (-40 °C to rt), gave a 31% yield of product 55 (Scheme 14). The same product was also obtained in 24% yield upon using 1.5 equiv. of PIDA and 0.2 equiv. of Cu(OTf)₂, at rt. On the other hand, reaction of dihydrofuran with 2 equiv. of bis(trimethylsilyl)uracil, 1.5 equiv. of PIDA, and 0.4 equiv. of TMSOTf (0 °C to rt), gave three products (56-58), shown in Scheme 14.

A proposed mechanism is shown in Scheme 14, where an initial addition product from dihydropyran undergoes reaction with bis(trimethylsilyl)uracil (either directly or via an oxocarbenium ion), followed by an elimination to yield 55. Alternatively, a double elimination from the initial addition product can produce a 2,3-dihydropyrylium ion that can undergo capture to yield 55. With dihydrofuran, product 56 can be obtained by elimination, as was the case with 55. But here, a rearrangement of the acetate can yield 57, while involvement of the amide carbonyl in the departure of PhI and AcO⁻ can yield cyclized product 58.

Next the oxidative coupling of enol ethers with bis(trimethylsilyl)uracil was studied using 1 equiv. each of the protected uracil, (PhSe)₂, PIDA, and 0.1 equiv. of TMSOTf. Reactions of dihydrofuran and dihydropyran were conducted at rt, that of ethyl vinyl ether at -5 °C, and those of the substituted dihydropyrans at -20 °C. Products from these reactions are shown in Scheme 15 as also a plausible mechanism for the reaction. From among the products, oxidation of compound 59 with m-CPBA in CH₂Cl₂ followed by exposure to pyridine in PhMe at 50 °C, gave compound 55 in an overall 60% yield.
Scheme 14. Reactions of dihydropyran and dihydrofuran with bis(trimethylsilyl)uracil.

Scheme 15. Various uracil derivatives prepared via the “seleno-glycosylation” approach and a possible mechanism.

The chemistry described above was then applied to the synthesis of dihydropyryl uracil and cytosine nucleoside analogues.²⁸ For this, compound 64 was synthesized over 6 steps from cis-2-butene-1,4-diol 1 (Scheme 16). Reaction of 64 with 1 equiv. each bis(trimethylsilyl)uracil, (PhSe)₂, PIDA, and 0.1 equiv. of TMSOTf, gave a 2 : 1 ratio of diastereomers 65a and 65b in 51% yield. The former was anticipated as the major product based on a conformational analysis of anticipated intermediates. These diastereomers could not be separated either after elimination (66a + 66b, 71% over 2 steps) or after deprotection at rt (67a + 67b, quantitative).

Acetylation of the hydroxyl groups of 67 gave chromatographically separable isomers 68a and 68b (Scheme 17). The amide groups in each isomer were converted to the sym-triisopropylphenylsulfonates and subjected to ammonolysis. Finally, the acetate protecting groups were removed with ammoniacal methanol (yield of 70a = 60% over two steps and that of 70b = 61% over two steps).

Scheme 17. Separation of the uracil nucleoside analogues and conversion to the cytosine derivatives.

3. Miscellaneous Hypervalent Iodine Reagent Mediated Nucleoside Modifications

In 1998, PIFA was utilized to introduce SPh and SePh groups into uracil derivatives and uridine analogues. The mechanism of this reaction (Scheme 18) is related to that shown in Scheme 15 and the reaction provides good yields of the products (Scheme 18). For sulfenylation the ratio of nucleosides/(PhS)$_2$/PIFA = 1 : 1 : 2, whereas for selenation it was 1 : 0.7 : 0.7.

It should be noted that PIDA/Br$_2$ and PIDA/I$_2$ have been used to halogenate pyrimidine derivatives at the C5 position, in 86-94% yields. However, details are not provided herein, as the chemistry has not been applied to nucleosides or nucleoside analogues.
Scheme 18. Sulfenylation and selenation of uracil derivatives and uridine nucleosides, and analogues.

Oxidation of oximes with hypervalent iodine reagents leads to nitrile oxides that can participate in [3 + 2] cycloadditions (Scheme 19). Such chemistry has been utilized to prepare a set of isoxazole-functionalized nucleoside analogues, circumventing the need for the isolation and manipulations of hydroximoyl chlorides.

Scheme 19. Use of PIFA for the cycloaddition of nitrile oxides with alkynes.
In 2016, a similar oxime oxidation was utilized to prepare purine derivatives with an appended isoxazole moiety. The precursor, (6-piperidin-1-yl)acetaldehyde was synthesized by reaction of 6-piperidin-1-yl-9H-purine with 2-bromoacetaldehyde diethyl acetal, with K$_2$CO$_3$ in DMF at 140 °C (µwave irradiation, 45 min, 83%). This compound was hydrolyzed to the aldehyde with HCl that was converted to the oxime $81$ by treatment with HONH$_2$·HCl in EtOH, in the presence of KOAc at 80 °C (2 h, 86%). Reaction of $81$ with propargylic alcohols yielded the corresponding isoxazole appended purine derivatives (Scheme 20). A phosphate derivative of propargyl alcohol also reacted ($83$).

Scheme 20. Formation of isoxazolyl 6-pyrrolidinyl purine derivatives by PIFA oxidation.

This chemistry was also applied to the synthesis of isoxazoline-modified 6-pyrrolidinyl purine nucleoside analogues. Best conditions involved the use of 10 equiv. of the olefinic alcohols or unsaturated phosphate esters, 1.5 equiv. of PIFA, and short reaction times (5-10 min). Some representative examples that were synthesized are shown in Figure 4.

Figure 4. Examples of isoxazoline-substituted 6-pyrrolidinyl purine derivatives via PIFA oxidation.

4. Purinyl N-Directed C–H Bond Oxidation Using PIDA

In 2011, efforts by others$^{33}$ and by us$^{34}$ led to the knowledge that the embedded purinyl nitrogen atoms can be used to direct C–H bond activation at remote sites in nucleosides. Both Pd(OAc)$_2$ and (ArRuCl)$_2$ catalysts were effective. The former was useable for ribonucleosides whereas the latter was more generally applicable across ribo and deoxyribonucleosides.

On the basis that the purinyl nitrogen atom appeared capable of directing a remote C–H bond activation, a single example was published in 2011 that showed that 6-phenylpurine ribonucleoside, protected as a
triacetate, could be oxidized in the aryl ring (Scheme 21, in this work, several purine derivatives were evaluated as well).\textsuperscript{35} The reaction gave mono and diacetoxylated products in a ~ 2.1 : 1 ratio (77% yield).

\textbf{Scheme 21.} Acetoxylation of an acetate-protected 6-phenyl purine ribonucleoside.

We had commenced our own independent studies on this bond oxidation at about the same time, but we had focused on the more labile 2'-deoxyribonucleosides.\textsuperscript{36} It has recently been quantitatively shown that 2'-deoxyribonucleosides are substantially more labile as compared to the ribosyl counterparts. For example, the $t_{1/2}$ for the deglycosylation of adenosine in 0.1 M HCl is 11 days at 37 °C. By contrast, the $t_{1/2}$ for deglycosylation of 2'-deoxyadenosine is 15 min.\textsuperscript{37}

\textbf{Figure 5.} Oxidation of 6-aryl purine nucleosides with Pd(OAc)$_2$ and PIDA (PG = t-BuMe$_2$Si).

In our investigations, we initially screened conditions for the C–H bond activation and oxidation using both 9-benzyl-6-phenyl-9$H$-purine and 6-phenyl purine 2'-deoxyribonucleoside with t-BuMe$_2$Si protecting groups on the saccharide. Whereas use of 5 or 10 mol% Pd(OAc)$_2$ with 1.2 equiv. of PIDA, in MeCN at 100 °C, gave identical product recoveries with the purine, use of 5 mol% Pd(OAc)$_2$ and 1.2 equiv. of PIDA gave incomplete
reaction with the nucleoside. On the other hand, 10 mol% of Pd(OAc)$_2$ and 1.5 equiv. of PIDA, in MeCN at 100 °C, gave a 57% yield of a monohydroxylated product (partial loss of the acetate was observed and so the product was treated with NaOMe/MeOH to fully hydrolyze the ester). As expected, the use of conditions reported in reference 35 yielded no product. Using this method, several hydroxylated nucleosides were prepared (Figure 5).

When partial hydrolysis of the ester was observed, the final product was obtained after exposure to NaOMe/MeOH. Reaction of the $p$-tolylphenyl precursor to 92 was conducted with 0.85 equiv. of PIDA as some undesired products were observed when 1.5 equiv. was employed. Reaction of the $p$-methoxyphenyl precursor gave mono and diacetoxylation products in a ~3.6 : 1 ratio.

Figure 6. Diacetoxylation of 6-aryl purine nucleosides with Pd(OAc)$_2$ and PIDA (PG = $t$-BuMe$_2$Si).

6-Aryl purine 2′-deoxy and ribonucleosides could also be dihydroxylated by using 15 mol % of Pd(OAc)$_2$ and 3 equiv. of PIDA. In all cases tested, the acetoxy group was not hydrolyzed. Reaction of the $p$-fluorophenyl precursor gave only 39% of the bis-oxidized product but 32% of the mono-acetoxylated product (98) was isolated from this reaction.

In the course of these investigations a dimeric cyclopalladated intermediate 105 was obtained from the reaction of a 6-(2-naphthalenyl)purine precursor (Scheme 22). This compound was a reasonable precatalyst for the acetoxylation of an arylpurine and a 6-arylpurine nucleoside, in the presence of PIDA. The crystallographically determined Pd–Pd bond distance in 105 was 2.844 Å. This is comparable to the bond distances in cyclopalladated dimers obtained from 2-phenylpyridine (2.862 Å) and 2-p-tolylpyridine (2.857 Å),$^{38}$ and benzo[h]quinoline (2.84 Å).$^{39}$ Thus, Pd–Pd interaction may be important for the formation of a Pd$^{III}$–Pd$^{III}$ bridged dimer 106, and species such as these are implicated in N-directed C–H bond oxidations.$^{39,40}$
Scheme 22. An isolated and crystallographically characterized cyclopalladated, Pd$^{II}$–Pd$^{II}$ dimer, and its potential conversion to a Pd$^{III}$–Pd$^{III}$ species by PIDA.

5. Cu-Catalyzed Intramolecular C–N Bond Formation in Purine Nucleosides Using PIDA

In 2012, PIDA and other oxidants (oxone, Fe$_2$(NO$_3$)$_3$·9H$_2$O, 1,4-benzoquinone, and K$_2$S$_2$O$_8$) were evaluated in combination with copper salts (CuI, CuBr, Cu(OAc)$_2$, and Cu(OTf)$_2$) for the cyclization of N$_6$-aryladenosine derivative, protected with acetyl groups on the sugar, to benzimidazolyl purine nucleoside analogues.\textsuperscript{41} 1.5 Equiv of PIDA and 5 mol% of Cu(OTf)$_2$ in 1 : 1 AcOH/Ac$_2$O, at 80 °C, proved to be optimal conditions. Using these conditions several benzimidazopurine ribonucleoside analogues were prepared (Scheme 23). It appears that the presence of a methyl or methoxy group at the ortho position to the amino group caused a reduction in the yield, as also did a naphthyl group.

Scheme 23. PIDA/Cu(OTf)$_2$-mediated cyclization of N$_6$-aryl adenosine triacetate derivatives to benzimidazopurine nucleoside analogues.

The mechanism of this reaction (Scheme 24) proposes a purinyl N$^1$ atom-directed cupration of the aryl ring, possibly via the tautomer. This would be followed by a reductive elimination, with PIDA reoxidizing the copper catalyst.
Scheme 24. A possible catalytic cycle for the Cu(OTf)$_2$/PIDA-mediated cyclization


As with the C–H bond oxidation chemistry, we were intrigued about the applicability of such a cyclization reaction to 2′-deoxyribonucleosides. As mentioned earlier, the 2′-deoxyribonucleosides are anticipated to be much more labile than the ribosyl counterparts, particularly those stabilized by electron-withdrawing acetates. We began our investigations by applying the previously described conditions$^{41}$ to silyl-protected N$^6$-phenyl 2′-deoxyadenosine ($\mathbf{116}$)$^{42}$. Not altogether surprisingly, we obtained a 11% yield of cyclized product $\mathbf{117}$, which was in stark contrast to the 88% obtained with $\mathbf{118}$ in previous work (Scheme 25)$^{41}$.

Scheme 25. Comparison of the reactivity of disilyl-protected N$^6$-phenyl 2′-deoxyadenosine to triacetyl-protected N$^6$-phenyl adenosine analogue.

This outcome prompted us to undertake a screening of conditions. We found that Cu(OTf)$_2$ in AcOH/Ac$_2$O, at 80 °C, was clearly detrimental, and in switching the reaction solvent to MeCN the yield improved from 11 to 39%, while in MeCN at 55 °C without Cu(OTf)$_2$ a good 61% yield of $\mathbf{117}$ was realized. PhMe, ClCH$_2$CH$_2$Cl, DMF, 1,4-dioxane, and MeNO$_2$ were investigated as solvents and yields ranged from 7-46%. However, in CF$_3$CH$_2$OH
(TFE) at 55 °C, a good 75% yield of 117 was observed, and in (CF₃)₂CHOH (HFIP), the reaction was faster in a comparable yield. With 1.3 equiv. of PIDA in HFIP at rt, an excellent 92% yield of 117 was obtained.

Using these conditions, several t-BuMe₂Si-protected N₆-aryl 2'-deoxyadenosine and adenosine analogues were assessed for this cyclization. In addition, one acetate-protected 2'-deoxyadenosine derivative and one acetate-protected adenosine derivative were also evaluated. The products from these reactions are summarized in Figure 7.

From these data, it can be clearly seen that most product yields were in the 80-92% range. The only case where a low yield was obtained was in the case of the naphthyl derivative (122, 38%). Notably, a low 40% yield was obtained with Cu(OTf)₂/PIDA (115 in Scheme 23). In fact the cyclization to 122 was conducted in MeCN as the substrate decomposed in HFIP. In our work, we isolated a second compound in this reaction and it was assigned imino quinone structure 123 on the basis of a ¹³C NMR resonance at δ = 185.1 ppm and the coupling constant of two coupled doublets in its ¹H NMR spectrum at δ = 6.70 and 7.05 ppm (J ≈ 10.5 Hz).

Scheme 26. Compounds synthesized using PIDA in HFIP, at room temperature.
Notably this chemistry is applicable to silyl- and acetyl-protected 2'-deoxyribonucleosides, as well as to silyl- and acetyl-protected ribosyl analogues. Furthermore, this chemistry appears scalable, because both compounds, 119 and 126, could be prepared on 0.9 mmol scale, in yields of 86 and 93%, respectively.

The mechanism of this transformation was probed using butylated hydroxytoluene (BHT) and 1,1-diphenylethene (DPE) as radical inhibitors. In three reactions, leading to 119, 121, and 127, either no product formation or only trace of product formation was observed, with substantial amounts of recovered starting material even with a single equivalent of the radical inhibitor. These data indicate that these reactions may proceed via radical cations or radicals (Scheme 26). Fluorinated solvents such as TFE and HFIP are known to stabilize radical cations that can be formed in reactions involving hypervalent iodine reagents.

A possible mechanism of this reaction could proceed via either formation of radical cation 132 that can cyclize to radical 133, or PIDA can react at the exocyclic amino group leading to 134. Fragmentation of 134 by a radical pathway can result in a resonance stabilized, nitrogen-centered radical (135/135') that can also cyclize to 133. Loss of a hydrogen radical from 133 will then lead to product. Notably, PhI was isolated in the 0.9 mmol-scale reactions. Also, the products displayed interesting fluorescence properties.

**Scheme 27.** A possible mechanistic pathway for the cyclization reaction with PIDA in HFIP.

A possible mechanism of this reaction could proceed via either formation of radical cation 132 that can cyclize to radical 133, or PIDA can react at the exocyclic amino group leading to 134. Fragmentation of 134 by a radical pathway can result in a resonance stabilized, nitrogen-centered radical (135/135') that can also cyclize to 133. Loss of a hydrogen radical from 133 will then lead to product. Notably, PhI was isolated in the 0.9 mmol-scale reactions. Also, the products displayed interesting fluorescence properties.

### 7. Pd-Catalyzed and Metal-Free Intramolecular C–N Bond Formation Leading to Isomeric Carbazolyl and Benzimidazolyl Purine Nucleoside Analogues Using PIDA

Most recently, we have studied cyclization of N₆-biarylyl adenine nucleosides. With these compounds two cyclization modes are possible; with the exocyclic N₆ atom leading to carbazolyl nucleoside analogues (route 1) or with the N¹ ring nitrogen atom leading to aryl benzimidazolyl nucleoside derivatives (route 2; Scheme 28).

We first investigated Pd-catalyzed reactions of 11 substrates (136–146) shown in Figure 7. The reactions involving Pd(OAc)₂ and PIDA are anticipated to proceed via a Pd²⁺/Pd⁴⁺ mechanism, where the hypervalent iodine reagent acts as an oxidant for the metal. In PhMe, at 55 °C, reactions were observed with all substrates...
except the trifluoromethyl-substituted ones (145 and 146). The ribosyl precursors 137 and 140 reacted comparably to the respective deoxy analogues 136 and 139. Reaction of the p-cyano precursor 144 gave a low product yield and in this case an iminoquinone byproduct 144' was also isolated and characterized.

Scheme 28. Two possible cyclization modes with N^6^-biaryl adenine nucleoside derivatives.

Figure 7. N^6^-biaryl adenine nucleoside substrates used for the reactions involving Pd(OAc)$_2$/PIDA (in cases where reaction was observed, red arrows indicate the site of C–N bond formation and the ensuing carbazolyl product yields are shown).
In the course of investigating solvent effects for the Pd-catalyzed reaction, we found that cyclization of compound 136 also occurred in HFIP and TFE as solvents, at 55 °C, but in the absence of a metal catalyst. Further investigations were conducted into this chemistry and the products from cyclization with PIDA in fluorinated solvents are shown in Figure 8.

Generally, these reactions in fluorinated solvents are superior to those catalyzed by Pd. With substrate 138, cyclization to the 1-position of naphthalene was observed, which is different from the outcome in the Pd-mediated approach where ring-closure occurred at the 2-position. Some substrates were sensitive to the more acidic HFIP and better to superior results were obtained in the less acidic TFE. With biarylyl substrates that bore an electron-withdrawing group on the ring more remote from purine (144, 145, and 146), cyclization occurred on the proximal ring, resulting in benzimidazolyl products (154–156).

When the solvent was changed from HFIP (or TFE) to MeCN, an interesting outcome was observed. In many cases where exclusive formation of carbazolyl nucleoside analogues was observed in the fluorinated solvent, competing formation of benzimidazolyl nucleoside derivatives was observed in MeCN. The results from the reactions in MeCN, at 55 °C, are summarized in Table 1. The only exceptions to benzimidazole formation were methoxy-substituted substrates 141 and 143. However, when the methoxy group in 141 was replaced with a phenoxy moiety in 142, a small amount of the benzimidazole isomer was observed.
withdrawing substituents on the ring remote from the purine led to benzimidazole formation in good yields (substrates 144–146).

Table 1. Results from the PIDA-mediated cyclization reactions of substrates 136–143, 145, and 146 in MeCN

<table>
<thead>
<tr>
<th>Entry</th>
<th>Substrate</th>
<th>Carbazole</th>
<th>Benzimidazole</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>136</td>
<td>147: 15%</td>
<td>157: 45%</td>
</tr>
<tr>
<td>2</td>
<td>137</td>
<td>148: 16%</td>
<td>158: 58%</td>
</tr>
<tr>
<td>3</td>
<td>138</td>
<td>149: 50%</td>
<td>159: 18%</td>
</tr>
<tr>
<td>4</td>
<td>139</td>
<td>150: 47%</td>
<td>160: 30%</td>
</tr>
<tr>
<td>5</td>
<td>140</td>
<td>151: 35%</td>
<td>161: 37%</td>
</tr>
<tr>
<td>6</td>
<td>141</td>
<td>152: 70%</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>142</td>
<td>153: 66%</td>
<td>162: 7%</td>
</tr>
<tr>
<td>8</td>
<td>143</td>
<td>152: 53%</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>144</td>
<td>–</td>
<td>154: 64%</td>
</tr>
<tr>
<td>10</td>
<td>145</td>
<td>–</td>
<td>155: 72%</td>
</tr>
<tr>
<td>11</td>
<td>146</td>
<td>–</td>
<td>156: 69%</td>
</tr>
</tbody>
</table>

DFT analysis showed that electron density at the nitrogen atoms in the purine ring decreased in the order: exocyclic N6 > N1 > N3 > N7 > N9. This indicated that both the exocyclic N6 and the ring N1 atoms can function as good nucleophiles. Interestingly, the electron density on the exocyclic N6 atom increased with introduction of electron-withdrawing substituents.

Whereas the Pd-catalyzed reactions are anticipated to proceed via PdII/PdIV redox via C–Pd σ-bond formation, the uncatalyzed reactions could involve interactions of the hypervalent iodine reagent with the nitrogen atoms of the purine ring, and proceed via either radical cations47–49 and/or nitrogen-centered radicals,50,51 and/or nitrenium ions.52–63 Extensive investigations with radical traps indicated that a single mechanism could not be ascribed to the uncatalyzed reactions and that overlapping mechanisms could be responsible for the products formed.
8. Conclusions

In this review, we have summarized some very interesting and unique reactions promoted by hypervalent iodine reagents. These range from Pummerer-type reactions that can be utilized for the development of sulfur and selenium analogues of natural nucleosides, as well as unnatural nucleosides. These reagents can also be used to prepare phenylsulfanyl and phenylselenyl pyrimidine nucleoside analogues, isoxazole-substituted and isoxazoline-based nucleoside analogues. The purinyl ring nitrogen atom can be used to direct C–H bond activation by palladium and oxidation, where PIDA plays a crucial role as oxidant. PIDA can also be used for metal-catalyzed and metal-free C–N, intramolecular bond forming reaction, leading to novel benzimidazopurine nucleoside analogues as well as carbazolyl nucleoside derivatives. As evidenced in this review, it is a reasonable expectation that hypervalent iodine reagents will continue to contribute significantly to the synthesis and modifications of nucleosides and nucleoside analogues.

Acknowledgements

Support by National Science Foundation Grants CHE-1265687 to MKL (for nucleoside modification chemistry described herein), and by CHE-1565754 to BZ, is gratefully acknowledged. Infrastructural support at The City College of New York has been provided by National Institutes of Health Grant G12 MD007603 from the National Institute of Minority Health and Health Disparities. We thank Dr. S. Satishkumar for a critical reading of this manuscript.

References

https://doi.org/10.1021/cr00038a006
https://doi.org/10.1016/j.tet.2014.12.066
https://doi.org/10.1366/12-06803
https://doi.org/10.1002/ijch.201300010
https://doi.org/10.1021/cr900301e
https://doi.org/10.1039/b612284c
https://doi.org/10.1590/S1516-89132007000300011
https://doi.org/10.1039/B305644A
https://doi.org/10.3987/COM-07-11250
https://doi.org/10.1021/jm034098e
https://doi.org/10.1016/j.tet.2010.11.038
https://doi.org/10.1016/j.tet.2011.08.020
https://doi.org/10.1016/j.tet.2016.08.071
https://doi.org/10.1002/chem.201300741
https://doi.org/10.1021/ol8012155
https://doi.org/10.1055/s-0031-1290749
https://doi.org/10.1055/s-0033-1340663
   https://doi.org/10.3987/COM-97-8074
   https://doi.org/10.1039/c0cc04646a
   https://doi.org/10.1021/ol200405w
   https://doi.org/10.1002/anie.201104035
   https://doi.org/10.1039/c1cc11135c
   https://doi.org/10.1021/jo4008282
   https://doi.org/10.1002/poc.3318
   https://doi.org/10.1021/ic902189g
   https://doi.org/10.1021/ja1054274
   https://doi.org/10.1021/ja906935c
   https://doi.org/10.1021/ol301848v
   https://doi.org/10.1039/C6CC07722F
   https://doi.org/10.1039/cc9600002105
   https://doi.org/10.1039/p29950001735
   https://doi.org/10.1002/cctc.201700918
   https://doi.org/10.1002/tcr.201500020
   https://doi.org/10.1021/jo00127a018
   https://doi.org/10.1021/ja00088a003
   https://doi.org/10.1021/jo991419e
   https://doi.org/10.1021/jo980450y
   https://doi.org/10.1002/anie.201102984
   https://doi.org/10.1021/ol302607y
   https://doi.org/10.1039/c0ob00749h
   https://doi.org/10.1016/j.tetlet.2006.07.050
   https://doi.org/10.1021/jo051252r
   https://doi.org/10.1039/b301330h
   https://doi.org/10.1039/b403081H
   https://doi.org/10.1021/jo0347009
   https://doi.org/10.1021/jo0260847
   https://doi.org/10.1246/cl.1990.581

Authors' Biographies

Mahesh K. Lakshman obtained the B.Sc. and M.Sc. degrees from the University of Bombay (Mumbai, India) and the Ph.D. degree from the University of Oklahoma. After completing a postdoctoral appointment at the National Institutes of Health (NIDDK), under a Fogarty Fellowship, he entered the private sector. He then joined the University of North Dakota and later moved to The City College of New York (The City University of New York system), where he rose to the level of Professor. He has served as Executive Officer of The City
University of New York Ph.D. Program in Chemistry and as one of two Vice Chairs of the Department of Chemistry & Biochemistry at The City College of New York. His research has been supported by the National Science Foundation and the National Institutes of Health. He is a Fellow of the Royal Society of Chemistry, a recipient of a Japan Society for the Promotion of Science Fellowship, and has been a Visiting Professor at the Indian Institute of Technology Bombay. In 2015, he and Professor Fumi Nagatsugi (Tohoku University) Guest-Edited a special issue of Molecules, entitled Nucleoside Modifications.

Barbara Zajc obtained the B.Sc., M.Sc., and Ph.D. degrees from the University of Ljubljana (Slovenia). She then undertook a sabbatical at the National Institutes of Health (NIDDK), under a Fogarty Fellowship. She returned to the University of Ljubljana where she was Docent and was then promoted to Associate Professor. In 2001 she moved to The City College of New York (The City University of New York system) as Associate Professor where she is now at the level of Professor. Her research has been supported by the National Science Foundation and the National Institutes of Health.